Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) stock fell -9.86% on Friday to $0.60 against a previous-day closing price of $0.67. With 1.1 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.22 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7100 whereas the lowest price it dropped to was $0.5799. The 52-week range on RVPH shows that it touched its highest point at $4.66 and its lowest point at $0.53 during that stretch. It currently has a 1-year price target of $9.67. Beta for the stock currently stands at 0.18.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RVPH was down-trending over the past week, with a drop of -11.83%, but this was down by -45.95% over a month. Three-month performance dropped to -60.26% while six-month performance fell -66.29%. The stock lost -82.35% in the past year, while it has lost -79.24% so far this year. A look at the trailing 12-month EPS for RVPH yields -0.98 with Next year EPS estimates of -0.96. For the next quarter, that number is -0.35. This implies an EPS growth rate of 53.40% for this year and 26.00% for next year.
Float and Shares Shorts:
At present, 15.13 million RVPH shares are outstanding with a float of 9.74 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.5 million, which was 3.32% higher than short shares on Jun 14, 2022. In addition to Dr. Laxminarayan Bhat Ph.D. as the firm’s Founder, CEO, Pres & Director, Mr. Narayan Prabhu serves as its Chief Financial Officer.
Through their ownership of 12.58% of RVPH’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.97% of RVPH, in contrast to 3.59% held by mutual funds. Shares owned by individuals account for 0.48%. As the largest shareholder in RVPH with 7.93% of the stake, Tang Capital Management LLC holds 1,200,000 shares worth 1,200,000. A second-largest stockholder of RVPH, The Vanguard Group, Inc., holds 463,652 shares, controlling over 3.06% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in RVPH, holding 78,075 shares or 0.52% stake. With a 2.34% stake in RVPH, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 353,326 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.69% of RVPH stock, is the second-largest Mutual Fund holder. It holds 103,986 shares valued at 0.11 million. Fidelity Extended Market Index Fu holds 0.38% of the stake in RVPH, owning 57,640 shares worth 63404.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, RVPH reported revenue of $0.00 and operating income of -$7.45M. Over the past year, revenue came in at $0.00 while operating income stood at -$15.68M. It generated -$7.37M net income for the quarter, which came to -$14.94M over the last twelve months. The EBITDA in the recently reported quarter was -$7.54M and diluted EPS was -$0.40. EBITDA for the full year was -$14.85M.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RVPH since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RVPH analysts setting a high price target of $3.00 and a low target of $3.00, the average target price over the next 12 months is $3.00. Based on these targets, RVPH could surge 400.0% to reach the target high and rise by 400.0% to reach the target low. Reaching the average price target will result in a growth of 400.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RVPH will report FY 2022 earnings on 03/20/2023. Analysts have provided yearly estimates in a range of -$1.30 being high and -$1.56 being low. For RVPH, this leads to a yearly average estimate of -$1.43. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Reviva Pharmaceuticals Holdings Inc. reported -$0.40 EPS. The surprise factor in the prior quarter was $0.06. Based on analyst estimates, the high estimate for the next quarter is -$0.31 and the low estimate is -$0.39. The average estimate for the next quarter is thus -$0.35.
Summary of Insider Activity:
Insiders traded RVPH stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 50,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 50,000 while 0 shares were sold.